Quick Answer
Boundless Bio, Inc. reported Stockholders Equity of $98.65 million for fiscal year 2025.
Boundless Bio, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $98.65M | -34.5% |
| 2024 | $150.64M | +218.5% |
| 2023 | -$127.08M | -55.6% |
| 2022 | -$81.70M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $110.17M | -33.3% | -10.2% |
| June 30, 2025 | $122.69M | -31.6% | -10.2% |
| March 31, 2025 | $136.59M | +196.7% | -9.3% |
| December 31, 2024 | $150.64M | +218.5% | -8.7% |
| September 30, 2024 | $165.08M | +242.3% | -7.9% |
| June 30, 2024 | $179.25M | +272.6% | +227.0% |
| March 31, 2024 | -$141.18M | -52.7% | -11.1% |
| December 31, 2023 | -$127.08M | -55.6% | -9.5% |
- Boundless Bio, Inc. showed a decrease of -34.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Boundless Bio, Inc.’s stockholders equity has grown by 220.8% (from -$81.70 million to $98.65 million).
- The most recent figure is from Boundless Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: